Broadly neutralizing antibodies (bNAbs) protect against HIV-1 infection, yet how they are generated during chronic infection remains unclear. It is known that T follicular helper (T FH ) cells are needed to promote affinity maturation of B cells during an immune response; however, the role of T FH during HIV-1 infection is undefined within lymph node germinal centers (GCs). We use nonhuman primates to investigate the relationship in the early stage of chronic SHIV AD8 (simian-human immunodeficiency virus AD8) infection between envelope (Env)-specific T FH cells, Env-specific B cells, virus, and the generation of bNAbs during later infection. We found that both the frequency and quality of Envspecific T FH cells were associated with an expansion of Env-specific immunoglobulin G-positive GC B cells and broader neutralization across HIV clades. We also found a correlation between breadth of neutralization and the degree of somatic hypermutation in Env-specific memory B cells. Finally, we observed high viral loads and greater diversity of Env sequences in rhesus macaques that developed cross-reactive neutralization as compared to those that did not. These studies highlight the importance of boosting high-quality T FH populations as part of a robust vaccine regimen aimed at eliciting bNabs.
INTRODUCTION
Most anti-HIV-1 broadly neutralizing antibodies (bNAbs) show a high degree of somatic hypermutation (SHM) (1) , suggesting that they have undergone extensive affinity maturation within germinal centers (GCs). Specialized follicular helper CD4 T (T FH ) cells support the formation of GCs and contribute to B cell differentiation, isotype switching, SHM, and the survival of high-affinity memory B cells and plasma cells through secretion of cytokines and chemokines [IL-4 (interleukin-4), IL-21, and CXCL13] and interactions with GC B cells via costimulatory receptors (2) (3) (4) (5) . T FH cells are characterized by high expression of Bcl6, CXCR5, and costimulatory receptors (PD-1 and ICOS) and low expression of CCR7. Simian immunodeficiency virus (SIV) infection of rhesus macaques (RMs) alters the CD4 T cell dynamic in lymph nodes (LNs), leading to T FH cell accumulation and increased egress of non-T FH cells (3) . This accumulation of T FH cells is associated with increased frequency of activated GC B cells in LN and SIV-specific antibodies in plasma. However, a direct role of T FH cells in eliciting broadly neutralizing responses against HIV remains unclear, and a deeper understanding may lead to new ways of analyzing vaccine potential in nonhuman primates.
Simian-human immunodeficiency virus AD8 (SHIV AD8 ) consistently establishes sustained viremia, causes unremitting depletion of CD4 T cells, and induces clinical immunodeficiency and death in inoculated RMs (6) . Many of the pathologic and immunologic consequences of HIV-1 infection can be observed in RMs infected with SHIV AD8 (6) . In particular, potent cross-clade NAbs against tier 1 and tier 2 HIV-1 isolates can be generated in some SHIV AD8 -infected RMs (7) (8) (9) .
Here, we investigated the relationship between the generation of broader cross-clade neutralizing activity and aspects of T FH cells, envelope (Env)-specific B cells, and viral replication during SHIV AD8 infection. We found that the frequency of Env-specific T FH cells and Env-specific immunoglobulin G-positive (IgG + ) GC B cells within the LN correlated with the subsequent development of NAbs in the chronic phase of infection. We also found that Env-specific T FH cells in monkeys with greater neutralizing activity expressed a gene profile skewed toward T FH and away from T helper 1 (T H 1) cells. Broader antibody neutralization was also associated with greater affinity maturation in memory B cells.
RESULTS

Longitudinal analysis of T FH cells and neutralization breadth in SHIV AD8 -infected macaques
Eight RMs were inoculated intrarectally with SHIV AD8 . All developed persistent infection (set point viremia: 10 2 to >10 5 RNA copies/ml) (Fig. 1A) , and all but one had a gradual loss of total circulating CD4 T cells (Fig. 1B) . We first determined the frequency of T FH cells in the LN of SHIV-infected RMs (3, 10, 11) . The CD28 dim CD95
low (hereafter referred to as naïve) CD4 T cells were used to set gates for the identification of particular populations within the CD28 high CD95 high [hereafter referred to as central memory (CM)] compartment ( fig. S1 ). CM CD4 T cells expressing a CXCR5 + PD-1 ++ phenotype were defined as T FH cells for further analyses. We observed variable accumulation of T FH cells in LN tissues beginning at 20 weeks and extending through 44 to 47 weeks post-infection (PI) (4.60 to 41.3%, Fig. 1C ). We next assessed whether the accumulation of T FH cells in LN was associated with general immune activation. The level of plasma soluble CD14 (sCD14), a marker of immune activation (12) , was significantly higher at 44 to 47 weeks PI compared to before infection (n = 8; P = 0.0234, Wilcoxon matched-pairs signed rank test; fig. S2A ). We also found that IL-6, a proinflammatory cytokine that is a critical regulator of T FH cells (3, 13, 14) , was increased at 20 weeks, substantially earlier than sCD14 ( fig. S2B ).
SHIV AD8 -infected RMs have been reported to develop cross-reactive NAbs between 34 and 50 weeks PI (7, 8) . We assessed neutralizing activity in plasma from all eight monkeys at multiple time points and found that neutralization activity against the related HIV-1 strain ADA arose between 44 and 47 weeks PI (Fig. 1D and fig. S3A ). To quantify the breadth and potency of the plasma neutralization activity, we assigned points based on ID 50 (50% inhibitory dilution) titers (one point for titers between 40 and 99, two points for titers between 100 and 999, and three points for titers ≥1000) for each virus in a multiclade 19-virus panel. We added these points together for an overall neutralization score. We observed a range of neutralization scores at 44 to 47 weeks PI (Fig. 1E) , with some RMs developing reasonably broad cross-clade responses (some against tier 2 HIV-1) by weeks 97 to 125 ( fig. S3B ). The neutralization score is treated as a continuous variable throughout the article, but for ease of visualization, the top three neutralizers are indicated in red, the middle three in blue, and the lowest two in black in all figures.
Generation of Env-specific T FH cells and GC B cells during SHIV AD8 infection B cell receptor (BCR) affinity maturation is dependent on T FH and antigenspecific B cell interactions in the GCs of LNs. We therefore determined the frequency of GC B cells in LN and memory B cells in peripheral blood 47  16  17  <10  102  45  <10  <10  1068  286  1344  54  290  1060  198  5287  11  3283  149  <10  27  BIH  44  <10  <10  <10  441  98  <10  <10  1091  384  5847  <10  1601  11  529 20,943 <10  3965  14  <10  22  G92  44  <10  <10  <10  53  116  <10  <10  316  235  5259  <10  88  237  172  1717  <10  1377  44  <10  22  DCT5  44  10  <10  <10  37  123  <10  <10  512  248  8958  <10  949  15  915  3021  <10  2777  <10  <10  19  JL4  44  <10  <10  <10  109  52  <10  <10  342  51  1519  <10  70  15  100  9819  <10  1413  28  <10  18  J78  44  <10  <10  <10  38  56  <10  <10  32  193  3265  <10  258  <10  507  968  <10  3869  <10  <10  15  FZH  47  <10  <50  <10  <10  <10  <10  <50  <50  33  915  <10  <50  <10  42  1546  <10  1724  <10  <10  9  JLD  44  <10  <10  <10  <10  13  <10  <10  16  14  891  <10  <10  <10  26  63  <10  132  <10 (Fig. 3A and fig. S8 ). Compared to other CD4 T cell populations such as naïve or non-T FH CM cells, the expression of Bcl6 is highest in T FH cells (Fig. 3B) . We next analyzed the relative gene expression of multiple T cell-associated transcription factors, cytokines, and chemokines in CD154 + Env-specific T FH cells in the RMs (2, 3, 15) . We found that Env-specific T FH cells expressed higher levels of Bcl6, MAF, MYB, IL-21, and CXCL13 and a lower level of IFNg compared to the non-T FH CM cells ( fig. S9A ). The expression of PRDM1 (Blimp-1) was not significantly different between non-T FH CM cells and Env-specific T FH cells. We further elucidated differences in populations by quantifying the expression levels of transcription factors related to T H 1 [TBX21 (T-bet)], T H 2 (GATA3), T H 17 (RORC), and T reg (T regulatory) (Foxp3) cells. There was no significant difference in TBX21, GATA3, RORC, and Foxp3 between non-T FH CM cells and Env-specific T FH cells ( fig. S9B ). To confirm the relevance of mRNA expression as measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR), we further quantified protein expression levels by flow cytometry for four main transcription factors. There was a robust correlation between mRNA and protein expression ( fig. S9C) . We then performed a clustering analysis of mRNA expression in T FH cells from each RM, and we detected a clear difference in Env-specific T FH cell gene expression between RMs with high (JG7, G92, and BIH) versus poor (FZH and JLD) neutralization scores (Fig. 3C ). The expression of T FH -related genes (Bcl6, MAF, MYB, CXCL13, and IL-21) and the T H 2-type gene (GATA3) were higher in RM with cross-reactive neutralizing responses as compared to those with poor or intermediate neutralizing responses. There was also a shift from a typical T FH cell gene expression profile to a more heterogeneous gene expression profile in these latter RMs. The expression of Foxp3 was lower in RM with high compared to low neutralization scores. These results indicate that the generation of broad neutralizing responses is associated with a distinct population of Env-specific T FH cells.
Development of cross-reactive neutralization activity and affinity-matured B cells
Production of cytokines IL-21 and IL-4 by T FH cells drives affinity maturation of BCRs within GCs (16-18). We therefore measured the level of SHM in the heavy chain variable gene (V H ) of single cell-sorted Envspecific IgG + B cells from bone marrow (BM) at weeks 44 to 47 PI. The whole variable region of heavy chains was PCR-amplified from individual Env-specific B cells and compared to a new database of RM V H gene germline sequences (19) . There was a large expansion of V H 4 family BCRs within all RMs ( fig. S9 ), a finding that may partially reflect the preferential usage of V H 4 in RM class-switched IgG B cells (20) . Overall, SHM accounted for between 0 and 18% of the nucleotides in the V H genes (Fig. 4A ). RMs with higher neutralization scores had fewer BCRs with low mutation rates (between 0 and 5%), but all RMs had expanded clonal families ( fig. S10 ). The mean level of SHM per animal correlated with both the magnitude of IL-4 + Env-specific T FH cells ( Fig. 4B ) and neutralization score of the RMs over time (Fig. 4C ). These data provide additional evidence of a link between degree of affinity maturation in memory B cells and ability to neutralize diverse strains of HIV.
To confirm that highly matured B cells were contributing to plasma neutralization, we cloned six of the identified YU2 gp140f-sorted BCRs from JG7, the RM that developed the broadest neutralizing response. These monoclonal antibodies (mAbs) represented three independent clonal families of highly mutated B cells (fig. S11A), and one family (JG7-VRC30) had an exceptionally long CDRH3 of 31 amino acids according to IMGT (international ImMunoGeneTics information system) definition (21) (fig. S11B ). Of these mAbs, only the four cloned from the JG7-VRC30 family were cross-neutralizing, and these affinitymatured antibodies recapitulated the tier 1 and 1B, but not the tier 2, plasma neutralizing activity ( fig. S11C ). Their neutralization profile was similar to that of the CD4-induced (CD4i) antibody 17b, and mapping data confirmed co-receptor specificity. Binding by these mAbs to gp120 was knocked down in the presence of an I420R mutation in the coreceptor binding site ( fig. S12A ), and they competed with 17b for binding to gp120 and increased binding of CD4-Ig to gp120 ( fig. S12B ). 17b is a human antibody with a long, acidic, tyrosine-rich CDRH3 that is directed against the co-receptor binding site of HIV-1 (22) , and this VRC30 family of antibodies appears to be the same type of antibody but originating in an SHIV-infected RM. Furthermore, these data corroborate that a highly mutated antibody lineage to a CD4i epitope contributes to some, but not all, plasma cross-reactivity at this time PI.
Diversity of viral sequences
We next evaluated the relationship between viral loads and neutralization scores. We found that set point viral load (the mean of log 10 viral loads from 8 to 44 weeks PI) correlated with neutralization score throughout infection (Fig. 5A) . Specifically, although neutralization scores slightly fluctuated, the RMs with the highest set point viral load had the highest neutralization scores at early (week 44) and later (week 120) times PI.
To examine viral diversity within the quasispecies, we performed single-genome amplification and env sequencing on longitudinal plasma samples from seven of the eight RMs. The gp160 sequences were aligned to the env gene of the transmitted/founder SHIV AD8-EO molecular clone (T/F), and maximum likelihood trees were constructed. Although most RMs had genetically homogeneous sequences early in infection (weeks 2 to 8), by week 8, viral diversity appeared evident in RMs with higher viral loads. It was not possible to sequence viral env genes in all RMs at all time points, especially those with low viral loads. Nevertheless, these phylogenetic trees highlight that the greatest viral evolution occurred in the RMs with the highest viral load set point and highest neutralization scores (Fig. 5B ). T FH cell and antibody neutralizing activity were detected between weeks 20 and 44 PI, which means that viral diversity appears to precede this development, because it was apparent in some RMs by 8 weeks PI. Furthermore, it is interesting to note that in the one RM with the highest neutralization score throughout infection, JG7, viral evolution appeared linear over time as compared to the increased branching seen in other monkeys' viral evolution. Overall, these data concur with findings in HIV-1 infection that viral set point, viral load, early env diversity, and time from infection all correlate with the development of neutralization breadth (23) (24) (25) .
DISCUSSION
Interaction of T FH and B cells in GCs is required for the orderly development and maturation of an antibody response (2, 4, 5) . Both HIV and SIV affect multiple aspects of this interaction, thereby altering the antibody response. Specifically, they infect and alter the dynamics, function, and transcriptional profile of T FH cells (3, 10, 11, 26) . Additionally, immune activation associated with infection can affect the cytokine and chemokine milieu of the GC where these critical interactions occur (3) . Although many changes in peripheral B cell and antibody responses have been described in HIV infection (27, 28) , how the altered interactions within the GCs affect the development of broad serum neutralization remains unclear. It has been observed that HIV infection induces a continuum of bNab responses (23, 29) , but the causative factors have not previously been delineated.
Infection of RMs with SHIV AD8 provides an ideal system in which to study the induction of cross-reactive neutralizing responses (6) (7) (8) , and development of neutralizing activity against two specificities (co-receptor and N332 supersite of vulnerability) has now been demonstrated (8) . In this model, we observed 13 variables that are highly correlated in a clustering analysis, including quality and quantity of T FH and GC B cells, viral set point, and neutralization score, and negatively correlated with non-T FH transcription factors such as FOXP3 and TBET (Fig. 6 and table S1 ).
Total T FH cells and IgG
+ GC B cells are not included in this cluster 1, suggesting that an increase in the frequency of total T FH cells is not sufficient to elicit breadth. This accumulation of total T FH cells could, by maintaining increased numbers of GC B cells, contribute to B cell abnormalities while also serving as a major target and source of progeny virions (11) . Alternatively, infection of T FH cells may produce the chronic Env antigen required to drive the GC reaction and lead to SHM within Env-specific B cells. Consistent with previous studies (10), we found A caveat to our findings is the limited number of macaques with which to conduct these experiments. Therefore, we were careful to not draw any conclusions based on any single macaque but rather all eight macaques as a continuum.
T FH cells are highly polyclonal in GCs, control the number of B cell divisions per GC cycle, and also regulate BCR hypermutation (18, 30) . GCs contain not only classical T FH cells but also CD4 follicular regulatory T (T FR ) cells (31) . We observed higher expression of T FH -related genes in the CD154 + Env-specific T FH cell population in RMs that developed neutralizing activity against multiple HIV clades as compared to those who did not. It is possible that the lack of persistent antigen and low Bcl6 expression during infection in these low neutralizing RMs explain this skewing (32) (33) (34) . The expression of Bcl6 may antagonize the development of a T H 1 or alternatively may be a result of a less-developed T FH phenotype in the low viremic animals. This finding indicates that not all T FH cells are the same and that induction of phenotypically defined T FH with a transcriptional profile skewed toward T FH and away from T H 1 and T FR is required to drive affinity maturation of the B cell response. Therefore, both quantity and quality of Env-specific T FH cells are important for maintaining Env-specific IgG + GC B cells and eliciting broader antibodies. Very few chronically infected individuals develop exceptional breadth, and an explanation for this rarity remains elusive. Previous reports have found that frequency of circulating memory T FH cells, length of HIV-1 infection, and level of plasma viremia are all associated with the development of breadth (23, 24, 35, 36) , in particular set point viral load and early env gene diversity (25) . Most HIV-specific bNAbs isolated from these special donors have high levels of SHM and/or long CDRH3s (37) . The B cells that produce these highly mutated antibodies are, by necessity, the products of multiple rounds of affinity maturation within GCs, leading to the generation of long-lived memory B cells or memory plasma cells that home to the BM (38) . Here, we analyzed early samples from <1 year PI, during which time modest cross-reactivity had developed. We observed higher levels of SHM in the V H genes of BM Env-specific IgG + memory B cells in RMs that developed broader NAb responses as compared to those who did not. Furthermore, we found a correlation between SHM, Env-specific T FH cells, and viral load set point. The fact that mAbs recapitulating some of the serum neutralizing activity were identified and showed extensive SHM confirms that highly affinity-matured B cells are contributing to the observed neutralization breadth. Epitope mapping of these mAbs also highlights the fact that these BCRs must go through affinity maturation against sites of vulnerability on the virus to neutralize diverse HIV strains. Furthermore, our observations concur with a recent study of an HIV-infected individual, demonstrating that diversification of the T/F virus precedes development of antibody breadth indicating B cell and virus coevolution (39) . It was recently reported that newly activated T cells can also enter established GCs (40) , raising the possibility that T cell escape may lead to the generation of T FH cells targeting new epitopes that can then join, and potentially prolong, the GC reaction. Overall, high viral load and env gene diversity appear to be the primary determinants of Env-specific T FH and GC B cell accumulation, which then drive the affinity maturation process. It is possible that a strong T H 1 response controls virus in the low neutralizing RMs; however, we found no correlation between frequency of Env-specific IFNg-producing CD8 cells and virus load.
Multiple memory T FH -like subsets have been identified in the blood that associate with antibody responses to vaccination (41, 42) , infection (35) , and autoimmune disease (43) , indicating that memory T FH -like cells in the blood could be a surrogate for T FH and GC reactions in secondary lymphoid tissues. Consistent with our previous studies (44) , we failed to detect a correlation between blood T FH -like subsets or antigen-specific blood T FH cells and neutralization activity ( fig. S13 ). Thus, in this model of chronic lentiviral infection, T FH -like memory cells in the blood were not directly indicative of T FH -B cell interactions in the LN. Our study can help address whether antigen-specific T FH cells generated in a chronic viral infection are beneficial or detrimental to the overall antiviral immune response. In mice, T FH cell expansion helps control chronic lymphocytic choriomeningitis virus infection (13) . However, T FH cell expansion is not associated with virologic control in HIV/SIV infection. The data suggest that the high levels of continuous Env antigen production are necessary for driving the GC reactions that lead to more effective antibody responses. It is possible that virologic control, whether through T cell, innate, or antibody-mediated mechanisms, could retard the evolution of NAbs.
How can we recapitulate these processes through vaccination? Because generalized immune activation and increased IL-6 production help drive T FH cell differentiation during HIV/SIV/SHIV infection, the selection of appropriate adjuvants for vaccination may be crucial. However, a number of adjuvants have been assessed and demonstrated no impact on SHM levels in Env-specific B cells as compared to unadjuvanted vaccines (19) . Because persistent production of viral Env glycoproteins appears to be essential to maintain T FH cells in LNs (10, 13, 45) , the use of replication-competent vectors may be required to maintain T FH cells for the length of time necessary to drive B cell affinity maturation. It is unclear if the expression of antigen in and by T FH cells, as seen in chronic HIV/SIV/SHIV infection, will be required of replication-competent vectors, or if cell-free expression will be sufficient. Finally, whether or not chronic antigen persistence, in the absence of sequence evolution, will drive the degree of affinity maturation and SHM required for a strong and broad NAb response remains to be determined.
Cluster 1 BLIMP (ET)
TBET ( Fig. 6 . Cluster analysis of significantly correlated variables. Pairwise Spearman correlations between 32 variables measured in this study were calculated using "rcorr." Insignificant correlations were given a correlation value of 0 (white), whereas significant correlations were clustered and visualized as a heat map on a scale between −1 (green) and 1 (pink). For variables that quantify gene expression, the ET of genes was measured in Env-specific CD154 + LN T FH . Highly correlated variables that cluster together are indicated.
MATERIALS AND METHODS
Study design
The overall objective of this study was to analyze the variables associated with T FH activation and B cell maturation during SHIV infection of RMs as a model for HIV-1 infection. Analysis of both gene and protein expression was performed on defined cell types and functional assays. There was no blinding or randomization of samples.
Virus
The origin and preparation of the tissue culture-derived SHIV AD8 swarm and molecular cloned stocks have been previously described (6, 7).
Animal experiments
Eight male and female RMs (Macaca mulatta) of Indian genetic origin ranging from 2 to 8 years of age were maintained in accordance with Guide for the Care and Use of Laboratory Animals Report no. NIH 85-23 (Department of Health and Human Services, Bethesda, MD, 1985) and were housed in a biosafety level 2 National Institute of Allergy and Infectious Diseases (NIAID) facility. Phlebotomies and sample collection were performed as previously described (46) . All animals were negative for the major histocompatibility complex class I Mamu-A*01, Mamu-B*08, and Mamu-B*17 alleles.
Quantification of viral nucleic acids Viral RNA levels in plasma were determined by real-time RT-PCR (ABI PRISM 7900HT sequence detection system; Applied Biosystems) as previously reported (46) .
Antibodies
We used the following directly conjugated antibodies: CD3-Cy7APC (allophycocyanin) (SP34-2), CD95-Cy5PE (phycoerythrin) (DX-2), CXCR3-Alexa 700, IL-4-Cy7PE (8D4-8), IFNg-FITC (fluorescein isothiocyanate), CD154-PE (TRAP1), IL-21-Alexa 647 IgG-APC, IgM-V450, and CD4-BV605 (all from BD Biosciences); CD8-BV785, CD20-BV570, CCR7-BV421, PD-1-BV785, ICOS-Pacific Blue, and streptavidin-BV650 (all from BioLegend); CD14-Qdot 800 (Invitrogen); CD28-ECD (CD28.2), CD19-ECD, and CD27-PC5 (Beckman Coulter); CXCR5-PerCP-eFluor 710 and CXCR5-APC (MU5UBEE) (eBioscience); and biotinylated anti-PD-1 (R&D Systems). Aqua amine viability dye was purchased from Invitrogen; IgD-FITC was obtained from SouthernBiotech; streptavidin-Cy7PE was obtained from Molecular Probes; and peanut agglutinin (PNA)-PE was purchased from GeneTex. To detect antigen-specific B cells, an uncleaved, stable trimerized gp140 YU2 protein was used (47) . The Avi-tagged YU2 gp140 protein was expressed, purified, and biotinylated using the biotin ligase BirA (Avidity) (48) . Biotinylation of the YU2 gp140 protein was confirmed by enzyme-linked immunosorbent assay (ELISA). The protein was then conjugated with the streptavidin-fluorochrome reagents, streptavidinCy7PE (Invitrogen).
Polychromatic flow cytometry
To detect antigen-specific T FH cells, we performed surface and intracellular cytokine staining of CD4 + T cells. Briefly, 4 × 10 6 to 5 × 10 6 LN cells were incubated in 1 ml of medium containing monensin (0.7 mg/ml; BD Biosciences) and brefeldin A (10 mg/ml; Sigma-Aldrich) in the absence or presence of peptides (15-mers overlapping by 11 residues) corresponding to full-length SIV Gag or HIV clade B Env [2 mg/ml each peptide, 5 ml/ml; National Institutes of Health (NIH) AIDS Reagent Program] for 8 hours. After washing, cells were stained with Aqua and anti-PD-1 biotin. Following a staining step with streptavidin, cells were surface-stained with titrated amounts of aCD4, aCD8, aCD20, aCD14, aCD28, aCD95, aCXCR5, and aCCR7. After fix/permeabilization, cells were stained with aCD3, aCD154, aIL-4, aIL-21, and aIFNg. Aqua was used to exclude dead cells from the analysis. Between 2 × 10 6 and 3 × 10 6 events were collected in each case. Electronic compensation was conducted with antibody capture beads (BD Biosciences) stained separately with individual mAbs used in the test samples. Data were analyzed using FlowJo version 9.7 (Tree Star). Forward scatter area versus forward scatter height was used to gate out cell aggregates. CD14 + , CD20 + , and dead cells were removed from the analysis to reduce background staining. To detect antigen-specific B cells, 2 × 10 6 to 3 × 10 6 PBMCs, LN cells, and BM cells were stained with Aqua and biotinylated YU2 gp140 probe on ice for 30 min. Following a staining step with streptavidin, cells were surface-stained with titrated amounts of aCD3, aCD8, aCD20, aCD14, aCD27, aIgD, aIgM, aIgG, and PNA. Forward scatter area versus forward scatter height was used to gate out cell aggregates. CD14 + , CD3 + , CD8 + , and dead cells were removed from the analysis to reduce background staining. To detect transcription factors, we performed surface and intracellular transcription factor staining of CD4 + T cells. Briefly, 4 × 10 6 to 5 × 10 6 LN cells were stained with aCD4, aCD8, aCD20, aCD14, aCD28, aCD95, aCXCR5, and aCCR7. After fix/ permeabilization by Transcription Factor Buffer (BD Biosciences), cells were stained with aBcl6 (clone K112-91 from BD Biosciences), aGATA3 (clone L50-823 from BD Biosciences), aT-bet (clone 4B10 from BioLegend), and/or aRORgt (clone Q21-559 from BD Biosciences).
Quantitative reverse transcription polymerase chain reaction mRNA was purified from sorted CD154 + T FH cells and analyzed using the SuperScript III Platinum One-Step qRT-PCR system (Invitrogen). For ease of data interpretation, "ET" values are reported throughout the article; these values are equal to 40 − C t and thus increase with greater expression of a transcript; they are proportional to log 2 RNA abundance. The two-way hierarchical clustering analysis was performed using JMP version 10. The following primers and probes were used: Bcl6 (Hs00277037_m1), IL-21 (Hs00222327_m1), c-MAF (Hs00193519_m1), GAPDH (glyceraldehyde phosphate dehydrogenase) (Hs99999905_m1),
Measurement of sCD14 and IL-6 levels sCD14 and IL-6 levels were determined in plasma by ELISA according to the manufacturer's instructions (R&D Systems, catalog no. DC140 for sCD14 and catalog no. D6050 for IL-6).
Neutralization assays
Plasma neutralizing activity against pseudotyped HIV-1 isolates and SHIVs was measured using the TZM-bl luciferase reporter gene assay as described (49, 50) . Pseudoviruses were diluted to obtain a baseline infection level of~200,000 relative light units. Neutralization curves were fit using a five-parameter hill-slope equation (50) . Reciprocal dilutions required to inhibit infection by 50% are reported as ID 50 s.
Sequence analysis of the heavy chain variable region of Env-specific B cells Antigen-specific B cells were single cell-sorted as previously described (51, 52 were single cell-sorted into 96-well PCR plates containing 20 ml of lysis buffer per well. The lysis buffer contained 0.5 ml of RNaseOUT (Invitrogen), 5 ml of 5× First-Strand Buffer (Invitrogen), 1.25 ml of 0.1 M dithiothreitol (DTT) (Invitrogen), and 0.0625 ml of Igepal (Sigma). RT was carried out by adding 3 ml of random hexamers (Gene Link) at 150 ng/ml, 2 ml of deoxynucleoxide triphosphate (dNTP) mix, each at 10 mM, and 1 ml of SuperScript III (Invitrogen) into each well for 42°C for 10 min, 25°C for 10 min, 50°C for 60 min, and 94°C for 5 min. The IgH variable region genes were amplified independently by nested PCR starting from 4 ml of complementary DNA (cDNA) as template. All PCRs were performed in 96-well PCR plates in a total volume of 25 ml containing water, 2.5 ml of 10× buffer, 0.5 ml of dNTP mix, each at 10 mM, 5 ml Q-Solution (Qiagen), 0.4 ml of HotStarTaq Plus DNA Polymerase (Qiagen), and 0.5 ml of primer or primer mix for each direction at 25 mM. For the first-round PCR 0.25 ml of MgCl 2 at 25 mM (Qiagen), Forward L1 primer mix, and Reverse 3′IgG(Outer) were used, whereas for the second-round PCR, the Forward SE primer mix and Reverse 3′IgG(Inner) were used as described before (51) . Each round of PCR was initiated at 94°C for 5 min, followed by 50 cycles of 94°C for 30 s, 55°C for the first round or 60°C for the second round for 30 s, and 70°C for 1 min, followed by 70°C for 10 min. The positive second-round PCR products were directsequenced with reverse PCR primers. Sequences containing stop codons, frameshifts, ambiguous nucleotide calls, or alignment lengths less than 250 nucleotides were not considered. Reads were further filtered for length, keeping only those between 300 and 600 nucleotides. Germline V genes were then assigned to each read using BLAST (Basic Local Alignment Search Tool) with empirically optimized parameters (53) . Reads for which no V gene match was found with an e value ≤10 −10 were discarded. ClustalW2 was used to calculate the sequence identity to the germ line of each BCR using a newly described RM database (19, 54) . BCR sequences were deposited in GenBank with accession nos. KM097097 to KM097988.
Cloning of highly mutated Env-specific B cells First-round PCR products for single cell-sorted YU2 gp140f-specific B cells were reamplified with custom primers containing restriction digest sites followed by subcloning, expression, and purification as described before (52) . Heavy chains were reconstituted as IgG1. The full-length IgG1 was expressed by cotransfection of 293 F cells with equal amounts of the paired heavy and light chain plasmids and purified using a recombinant protein A column (GE Healthcare). The antibody names are designated with a "donor-antibody lineage.clone" convention. Sequences of cloned heavy and light chain mAbs JG7-VRC30.01-VRC32.01 were deposited in GenBank with accession nos. KM103065 to KM103076.
Viral RNA extraction and cDNA synthesis From each plasma specimen, at least 20,000 viral RNA copies were extracted using the QIAamp Viral RNA Mini kit (Qiagen). RT of RNA to single-stranded cDNA was performed using SuperScript III Reverse Transcriptase according to the manufacturer's recommendations (Invitrogen). In brief, a cDNA reaction of 1× RT buffer, 0.5 mM of each dNTP, 5 mM DTT, RNaseOUT [RNase (recombinant ribonuclease) inhibitor] (2 U/ml),SuperScript III Reverse Transcriptase (10 U/ml), and 0.25 mM antisense primer SIVEnvR1 5′-TGTAATAAATCCCTTCCAGTCCCCCC-3′ was incubated at 50°C for 60 min and 55°C for 60 min and then heatinactivated at 70°C for 15 min followed by treatment with 2 U of RNase H at 37°C for 20 min. The newly synthesized cDNA was used immediately or frozen at −80°C.
Single-genome amplification of SHIV env A 3.3-kb fragment that includes the entire env gene was sequenced from each animal at various time points after infection using a limiting dilution PCR so that only one amplifiable molecule is present in each reaction. Single-genome amplification was performed by serially diluting cDNA distributed among independent PCRs to identify a dilution where amplification occurred in <30% of the total number of reactions. PCR amplification was performed with 1× PCR buffer, 2 mM MgSO 4 , 0.2 mM of each dNTP, 0.2 mM of each primer, and Platinum Taq High Fidelity polymerase (0.025 U/ml) (Invitrogen) in a 20-ml reaction. First-round PCR was performed with primer SIVEnvF1 5′-CCTCCCCCTCCAGGACTAGC-3′ and antisense primer SIVEnvR1 under the following conditions: 1 cycle of 94°C for 2 min and 35 cycles at 94°C for 15 s, 55°C for 30 s, and 68°C for 5 min, followed by a final extension of 68°C for 10 min. Next, 1 ml from the first-round PCR product was added to a second-round PCR that included the sense primer SHIVEnvF2 5′-GACCTCC-AGAAAATGAAGGACCAC-3′ and antisense primer SIVEnvR2 5′-ATGAGACATRTCTATTGCCAATTTGTA-3′ performed under the same conditions used for first-round PCR, but with a total of 45 cycles. Correct sized amplicons were identified by agarose gel electrophoresis and directly sequenced with second-round PCR primers and nine HIVspecific primers using BigDye Terminator technology (Applied Biosystems). To confirm PCR amplification from a single template, chromatograms were manually examined for multiple peaks, indicative of the presence of amplicons resulting from PCR-generated recombination events, Taq polymerase errors, or multiple variant templates.
Sequence alignments, diversity, and phylogenetic analysis Sequences were codon-aligned to the infecting transmitted founder (T/F) clone SHIV AD8-EO-RQ and manually edited using Geneious version 6 (Biomatters; www.geneious.com/). The env sequences containing unproductive mutations (such as those that cause stop codons and frameshifts) were removed from further analysis. Maximum likelihood trees were constructed using RaxML on the CIPRES Science Gateway (1) and visualized as rooted to the T/F using the FigTree program. All sequences were deposited in GenBank with accession nos. KM082157 to KM082524.
Enzyme-linked immunosorbent assay
ELISAs were performed as previously described (52) . Briefly, 96-well ELISA plates were coated with the specified recombinant protein (2 mg/ml) in phosphate-buffered saline (PBS) overnight at 4°C. The following day, the plates were blocked with B3T buffer (150 mM NaCl, 50 mM trisHCl, 1 mM EDTA, 3.3% fetal bovine serum, 2% bovine albumin, and 0.07% Tween 20) and incubated with fourfold serial dilutions of heatinactivated plasma starting at a dilution of 1:100 followed by peroxidaseconjugated goat anti-human IgG antibody (Jackson ImmunoResearch). All incubations were for 1 hour at 37°C, and all volumes were 100 ml except that for blocking, which was 200 ml. Plates were washed between each incubation with 0.1% Tween 20 in PBS, detected using SureBlue TMB (3,3′,5,5′-tetramethylbenzidine) substrate (Kirkegaard & Perry Laboratories), and subsequently read at 450 nm. For competition ELISA, plates were coated with sheep anti-gp120 C5 antibody (1 mg/ml) (Aalto Bio Reagents) overnight and then used to capture YU2 gp120 protein. After blocking, serial dilutions of competition antibodies were added for gp120 binding followed by biotin-labeled JG7-VRC30.02 (150 ng/ml) for 1 hour. Plates were next incubated with streptavidin-horseradish peroxidase (250 ng/ml) (Sigma) and developed with TMB as described above.
Statistical analysis
Statistical methods used here comply with journal guidelines. Experimental variables were analyzed using the Wilcoxon matched-pairs signed rank test with normal-based 95% confidence interval; correlations were performed using the nonparametric Spearman rank test and linear regression analysis. Bars depict median values, and P values of <0.05 were considered significant. The GraphPad Prism statistical analysis program (GraphPad Software) was used throughout. For analysis of all 32 variables measured during infection, pairwise correlations with significance levels were calculated using rcorr from the R package "Hmisc." When a pairwise correlation was determined to be significant, the correlation value was retained. When a correlation was determined to be insignificant, the correlation value was set to zero. The remaining significant correlations were then clustered and visualized as a heat map using the R package "heatmap.2."
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